Hyperuricemia
Conditions
Interventions
Hydrolyzed casein peptide complex group:Hydrolyzed Casein Peptide Compounding Products+Flavor correction agent + Color correction agent
Hydrolyzed casein peptide group:Hydrolyzed casein peptide+Flavor correction agent + Color correction agent
Placebo group:Flavor correction agent + Color correction agent
Sponsors
Medical College of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Meet the above Western medical diagnostic standards; 2) Those who are older than or equal to 18 years old and less than or equal to 75 years old; 3) Patients with a history of gouty arthritis attacks, who have not had an attack within 1 month and are currently in a stable state; 4) Fasting blood glucose < 7.0mmol/L, blood glucose < 11.1mmol/L 2 hours after meals; 5) Have not taken other traditional Chinese medicines or uric acid-lowering drugs recently; 6) Those who have not used drugs that have serious effects on liver and kidney function within 3 months; 7) Sign the informed consent form, understand the content of the research, and be able to independently cooperate in completing the research.
Exclusion criteria
Exclusion criteria: 1) Patients with hyperuricemia who have previously developed gout; 2) Patients with urinary uric acid stones; 3) Patients with secondary hyperuricemia caused by other causes; 4) Patients with diabetes, cardiovascular and cerebrovascular, liver, kidney and other major diseases; 5) alcoholics, pregnant and lactating women and psychiatric patients; 6) Patients with severe allergies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum uric acid decreases from baseline; | — |
Secondary
| Measure | Time frame |
|---|---|
| Four-level evaluation of clinical efficacy;Incidence of gout attacks;Measured change in erythrocyte sedimentation rate (ESR) from baseline;Measured changes in liver and kidney function (ALT, AST, BUN, Cr, GFR) from baseline;Measured change in C-reactive protein (CRP) from baseline;The measured changes of four lipids (TC, TG, HDL-C, LDL-G) from the baseline period;Measured change in fasting blood glucose (GLU) from baseline;Measured change in interleukin-lß (IL-lß) from baseline;Changes in urine pH from baseline, measured values and decreases;Measured and decreased changes in blood pressure from baseline; | — |
Countries
China
Contacts
Public ContactJin Sun
Medical College of Qingdao University
Outcome results
None listed